Accendra Health announced it will not implement an at-the-market equity issuance program intended to reduce indebtedness, citing current market conditions and sufficient liquidity from its undrawn $300 million revolving credit facility. The company confirmed the closure of one non-core asset sale in Q3 and expects a second to close by year-end, generating approximately $45 million in cash with de minimis impact on Adjusted EBITDA. Additionally, the Board plans to announce a new CEO successor by mid-September 2026, ahead of outgoing CEO Mr. Pesicka's planned retirement at the end of the year. Accendra Health is a provider of home-based care products and services for chronic conditions.

Accendra Health declared a dividend of one preferred share purchase right for each outstanding common share to preserve net operating losses and other tax attributes under a Section 382 Rights Agreement dated August 10, 2026. The record date is August 20, 2026, with rights attaching to common stock certificates until distribution or triggering events occur. Each right entitles the holder to purchase one-thousandth of a Series C Cumulative Preferred Share at $15.00 per unit, subject to adjustment upon an ownership change where any person acquires beneficial ownership of 4.9% or more of outstanding shares. The plan expires on August 10, 2029, unless terminated earlier by the Board. Accendra Health operates in the healthcare sector, providing products and services for home-based care.

Accendra Health reported second quarter 2026 financial results, posting $613.2 million in net revenue and a GAAP loss from continuing operations of $89.1 million ($1.16 per share). The company reduced total debt by $385 million through a balance sheet optimization transaction completed in June, which included the issuance of new secured notes due 2032 and 2033. CEO Edward A. Pesicka announced his intention to retire by the end of 2026. Full-year 2026 guidance was updated to $2.45–$2.55 billion in revenue, $300–$320 million in adjusted EBITDA, and breakeven to slightly positive free cash flow. Accendra Health operates in the home healthcare industry, providing products and services for chronic conditions such as diabetes, sleep health, and respiratory care.

Accendra Health announced that President and CEO Edward A. Pesicka intends to retire by the end of 2026 or upon the appointment of a successor. The Board has initiated a search for his replacement, leveraging its existing succession planning process. Mr. Pesicka may serve in an advisory capacity during the transition. His departure follows significant strategic moves including the divestiture of Owens & Minor and balance sheet optimization. Accendra Health operates as a provider of products, technology, and services supporting home-based care for patients with chronic conditions.

Accendra Health, Inc. announced the final results of its exchange offers and consent solicitations for its 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. The company issued $539.25 million in First Lien Notes and $698.1 million in Second Lien Notes in exchange for the tendered and accepted Existing Notes. Accendra Health, Inc. is a healthcare company providing health services.

Accendra Health, Inc. announced early results of its exchange offers and consent solicitations for its 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030. The company issued $539.25 million in 9.000% First Lien Notes due 2032 and $698.0 million in 9.750% Second Lien Notes due 2033. Additionally, the company established a new $300.0 million revolving credit facility due in 2030. Accendra Health, Inc. is a healthcare services company.